Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 25, 2017 - The FDA approved Cyltezo (adalimumab-adbm), Boehringer Ingelheim’s (BI) biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
